Modified immune cells for T-cell leukemia/lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of immunotherapy called anti-CCR9 CAR T cells for people whose T-cell leukemia or lymphoma has not responded to standard chemotherapy. The treatment uses your own immune cells that are modified in a lab to find and attack cancer cells that have a specific marker (CCR9) on their surface.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your leukemia or lymphoma (T-ALL or T-LBL) has come back or not responded to at least one round of chemotherapy (if you are 18 or older) or two rounds (if under 18).
- Your cancer cells must have a protein called CCR9 on their surface (checked by a lab test).
- If you have lymphoma (T-LBL), you must have tumor that can be measured by scans or exams.
- You must be generally well enough to be up and about (ECOG score 2 or less for age ≥10, or Lansky score >50% for age <10) and not have active GVHD after a prior stem cell transplant.
- You cannot have active cancer in the brain/spinal cord, uncontrolled infections (like hepatitis B/C, HIV), serious heart or organ problems, or be pregnant/breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using specially engineered immune cells (CAR T cells) from a past stem cell donor to attack cancer cells in people with certain types of T-cell cancers that have returned after a stem cell transplant. The goal is to see if this treatment can lead to remission so a second stem cell transplant can be done.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
This early-phase trial tests CAR T-cells made to attack leukemia cells with specific markers (CD19 and CD22). It may help people with difficult-to-treat, relapsed, or high-risk acute lymphoblastic leukemia (ALL), especially when standard treatments haven’t worked well.
This trial tests a new immune cell treatment (called CAR-T) that has been modified to help the cells stay active longer. It is designed for adults with B-cell leukemia or lymphoma who cannot tolerate strong chemotherapy, offering a potentially gentler option.
This study tests a new type of immune therapy called CAR-T cells, which are made from your own blood cells to find and attack cancer. It is for adults with leukemia or lymphoma that has come back or is hard to treat.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
Hear when a new T-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.